4.1 Maintenance of Registration

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive



Introduction : Maintenance of Registration



Re-Registration Process



Re-Registration Fees



Rejection of Application


Registration of a product shall be valid for five (5) years or such period as specified in the Authority database (unless the registration is suspended or cancelled by the Authority).

Application for re-registration (renewal of product registration) of a product shall be submitted within six (6) months prior to the expiry of the validity period of a product registration. A letter of reminder for product re-registration will be issued to the product registration holder 3 months prior to the expiry date of a product registration.

After the expiry date, the status of product registration shall be automatically changed to ‘expired’, and applicant will not be able to submit the application for product re-registration. Any form of appeal shall not be considered if re-registration application is not submitted before the expiry date of a product registration since reminder letter is issued 3 months prior to the expiry date. A new registration application shall be submitted if applicant wishes to continue to market the product.

After the expiry of product registration date, the product is deemed unregistered. Products of which their re-registration is on hold due to unmet requirements but has passed its registration expiry date, the new registration date shall be updated according to the DCA Meeting date where the re-registration application is approved by the DCA.

The application for product re-registration shall only be submitted when all of the registration requirements have been complied with. Failure to do so shall result in the re-registration application being rejected by the Authority.





The requirements for product re-registration as aforementioned are as follows:

a)    Patient dispensing pack size for pharmaceutical product containing scheduled poison or non-scheduled poison with tablet/capsule dosage form, including oral liquid preparation and dermatological preparation.

Note: Please refer Appendix 23: Guideline on Patient Dispensing Pack for Pharmaceutical. 

b)    Bioequivalance study report for all registered generic products containing scheduled poison with immediate release, oral, solid dosage form (came into force starting from 1st January 2013)


1. (10) dlm.BPFK/PPP/01/03 Jld.1 - Arahan Pengarah Kanan Perkhidmatan Farmasi Bil 1 Tahun 2011 : Direktif Penguatkuasaan Keperluan Kajian Bioekuivalens Bagi Semua Produk Generik “Immediate Release, Oral, Solid Dosage Form” Yang Mengandungi Bahan Aktif Racun Berjadual Serta Akreditasi Pusat Kajian BioEkuivalens (2 March 2011)

2. Bioequivalence study report for all registered generic products containing scheduled poison with effervescent, dispersible, orodispersible, sublingual, buccal and chewable dosage form (comes into force for product registration which is expiring starting from 1st January 2019)

3. Direktif Permohonan Pendaftaran Semula Produk Yang Pernah Didaftarkan Secara Pendaftaran Hak Dan Produk Not Commercially Viable Medicine (NCVM). 

4. Direktif Mengenai Penerimaan Pengesahan Pematuhan Amalan Perkilangan Baik (APB) Bagi Pegilang Farmaseutikal Bagi Tujuan Pendaftran Baru/ Pendaftaran Semula Produk Farmaseutiakl Berdaftar Dengan Pihak Berkuasa Kawalan Dadah (PBKD) 

5. Direktif Kaji Semula Pendaftaran Produk untuk Tujuan Eksport sahaja/ For Export Only (FEO)

6. Direktif untuk pendaftaran semula bersyarat bagi produk farmaseutikal berdaftar yang masih belum memenuhi keperluan data kajian stabiliti dalam zon IV B.

7. Pekeliling Pendaftaran Semula Bersyarat Bagi Produk Generik Berdaftar Yang Masih Belum Memenuhi Keperluan Kajian Bioekuivalens (BE) Semasa Proses Pendaftaran Semula Dan Produk Generik Yang Telah Digantung Pendaftaran Kerana Penilaian Laporan Kajian BE Didapati Tidak Memuaskan

8. Arahan Pengarah Kanan Perkhidmatan Farmasi Bil. 11 Tahun 2016 - Penerimaan Pengesahan Pematuhan APB Bagi Tujuan Pendaftaran Semula Produk Farmaseutikal Berdaftar

9. Pendaftaran Semula Bersyarat bagi Produk Generik Berdaftar yang Mengandungi Bahan Aktif Racun Berjadual dalam Bentuk Immediate Release, Oral, Solid Dosage Form yang belum Memenuhi Keperluan Kajian Bioekuivalens (BE) Semasa Pendaftaran Semula Produk dan Produk Generik di mana Penilaian Laporan Kajian BE didapati Memuaskan

10. Arahan Pengarah Kanan Perkhidmatan Farmasi Bilangan 1 Tahun 2016 - Direktif Mengenai Keperluan Pemeriksaan Amalan Perkilangan Baik (APB) Luar Negara bagi Tujuan Pendaftaran / Pendaftaran Semula Produk Farmaseutikal Berdaftar dengan Pihak Berkuasa Kawalan Dadah (PBKD)

11. Pekeliling Kawalan Produk Persediaan Parenteral Sebagai Racun di bawah Akta Racun 1952

12. Direktif Untuk Menguatkuasakan Penggunaan Guideline For Registration Of Drug-Medical Device And Medical Device-Drug Combination Products

13. Pekeliling Penggunaan Nama Generik Pada Nama Produk Bagi Produk Farmaseutikal




The application for product re-registration shall be submitted and herein paid via the current online system.

a)    The non-refundable processing fees for product re-registration are as follow:


Traditional Product                               

RM 500.00 per product


Pharmaceutical Product (including Health Supplement)       

RM1,000.00 per product 




Refer to Appendix 24: Appeal.


National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti (Jalan Profesor Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075


The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Thursday 23 September 2021, 13:37:00.
© Copyright 2019 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Main Menu English

Choose Your Language